This tiny biotech spun a quick $2 billion from $12 million
October 18, 2018 at 10:04 AM EDT
Endocyte licensed a prostate cancer drug a year ago for an upfront payment of $12 million. Now, it’s being bought by the Swiss pharma giant Novartis for more than $2 billion.